Advertisement

Advertisement

Leukemia
Lymphoma
Immunotherapy

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma: CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

In a Chinese study reported in The New England Journal of Medicine, Hu et al found that sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) without graft-vs-host disease (GVHD) prophylaxis was effective in patients with...

Lymphoma
Geriatric Oncology
Cardio-oncology

Older Patients With Newly Diagnosed Hodgkin Lymphoma: Preexisting Heart Failure and Survival Outcomes

In a study reported in JACC: CardioOncology, Upshaw et al found that preexisting heart failure was associated with an increased risk of lymphoma and cardiovascular mortality among patients aged ≥ 65 years who were newly diagnosed with Hodgkin lymphoma. The study used linked Surveillance,...

Issues in Oncology
Breast Cancer
Lymphoma

Breast Implant–Related Cancers: Should Our Patients Be Concerned?

The U.S. Food and Drug Administration (FDA) issued a safety communication,1 which was updated2 on March 22, 2023, informing the public that there have been reports of squamous cell carcinomas (SCC) and various lymphomas of the breast in the capsule or scar of breast implants. These lymphomas are ...

Lymphoma

Zanubrutinib in Relapsed or Refractory Follicular Lymphoma

On March 7, 2024, the Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa) was granted accelerated approval in combination with the monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy...

Lymphoma

Advanced-Stage Classical Hodgkin Lymphoma

Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...

lymphoma

Third-Line Treatment of Relapsed/Refractory Follicular Lymphoma in a Patient With High-Risk Features

This is Part 3 of Treatment Options for Relapsed/Refractory Follicular Lymphoma: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew M. Evens, L. Elizabeth Budde, and Carla Casulo discuss the third-line treatment of relapsed/refractory follicular lymphoma in a patient with high-risk features. The patient is a 65-year-old Black man who was initially diagnosed in 2014 and treated with R-CHOP followed by 2 years of rituximab maintenance. After his disease progressed in 2020, he was treated with bendamustine/obinutuzumab, obtaining a complete response, and then received obinutuzumab maintenance until April 2022. In February 2023, he presented with increasing abdominal pressure, fatigue, and drenching night sweats. A PET scan revealed multifocal disease progression, including a bulky left lower quadrant soft tissue mass near the lumbar spine. A biopsy confirmed grade 3 follicular lymphoma with prominent necrosis and multiple patches of large cells; it was positive for CD20, CD10, BCL-2, and BCL-6, and the Ki-67 was 60% to 70%.   In the conversation that follows, the faculty discuss treatment options for patients with high-risk features, choosing between CAR T-cell–based therapies and bispecific antibodies in the third-line setting, and important considerations when administering CD3/CD20-targeted bispecific antibodies in the community setting.

lymphoma

Relapsed Follicular Lymphoma With POD-24

This is Part 2 of Treatment Options for Relapsed/Refractory Follicular Lymphoma: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew M. Evens, L. Elizabeth Budde, and Carla Casulo discuss the management of patients with follicular lymphoma who experience progression of disease within 24 months (POD-24). The patient is a 71-year-old fit, White man who presented with fatigue and diffuse lymphadenopathy. After undergoing an excisional node biopsy, he was found to have follicular lymphoma grade 1/2 out of 3. A staging PET scan showed multiple hypermetabolic lesions. He received bendamustine/rituximab induction therapy for 6 cycles and obtained a metabolic complete response; he did not receive rituximab maintenance. Eight months later, he presented with swelling of the right eyelid with new, painful soft tissue lesions. A PET scan showed multiple hypermetabolic subcutaneous nodules in the upper back, left inguinal and right inguinal nodes, and right lateral thigh.   In the conversation that follows, the faculty discuss the meaning and clinical implication of POD-24, optimal treatment options for patients who experience early recurrence, and whether autologous stem cell transplant is still an option in 2024.

lymphoma

Second-Line Treatment of Relapsed Follicular Lymphoma in a Patient With Comorbidities

This is Part 1 of Treatment Options for Relapsed/Refractory Follicular Lymphoma: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew M. Evens, L. Elizabeth Budde, and Carla Casulo discuss the second-line treatment of relapsed follicular lymphoma in a patient with comorbidities. The patient is a 74-year-old Asian man who was diagnosed 5 years ago with follicular lymphoma grade 1/2 out of 3 and a Ki-67 score of 5% to 10%. His ECOG performance status was 1, but he had multiple comorbidities that led to a CIRS-G score of 12. After achieving a metabolic complete response on single-agent rituximab therapy, he received 2 years of rituximab maintenance therapy. Remission was maintained for 4 years, but 18 months after his last rituximab, he presented with right leg swelling that was negative for deep vein thrombosis. A coronal PET/CT scan showed a new large retroperitoneal mass abutting the right psoas and iliopsoas muscles, encasing his iliac vessels and ureter.   In the conversation that follows, the faculty discuss the importance of repeat biopsy and molecular testing in patients with relapsed follicular lymphoma, how past medical history and comorbidities influence treatment choice, and the clinical implications of the AUGMENT trial.

Lymphoma

B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab

As reported in the Journal of Clinical Oncology by L. Elizabeth Budde, MD, PhD, and colleagues, extended follow-up of the dose-escalation phase of a phase I/II trial showed that the CD20 x CD3 T-cell–engaging bispecific antibody mosunetuzumab-axgb—given as an off-the-shelf fixed-duration outpatient ...

Lymphoma

Mantle Cell Lymphoma: Front-Line Therapy

“The practice of medicine is an art, not a trade….” —Sir William Osler Mantle cell lymphoma (MCL) accounts for approximately 5% to 7% of all lymphomas; the median age of patients with MCL is between 60 and 70 years. This lymphoma is generally considered incurable. Median survival in retrospective...

Leukemia
Lymphoma
Immunotherapy

Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL

On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...

Lymphoma

Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?

For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...

Lymphoma

FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma

On March 7, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule BTK inhibitor zanubrutinib (Brukinsa) in combination with the anti-CD20 monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of ...

Lymphoma

Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of Ro-CHOP Trial

As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously...

Breast Cancer
Lymphoma
Survivorship

Doxorubicin Exposure and Risk of Breast Cancer in Survivors of Hodgkin Lymphoma

In a Dutch study reported in the Journal of Clinical Oncology, Neppelenbroek et al found that doxorubicin treatment was associated with an increased risk of breast cancer among adolescent and adult Hodgkin lymphoma survivors. Study Details The study involved a cohort of 1,964 female 5-year Hodgkin...

Leukemia
Lymphoma
COVID-19

COVID-19 Risk in Pediatric Patients Receiving Treatment for Acute Lymphoblastic Leukemia or Lymphoma

In a retrospective case series reported in JAMA Network Open, Hashmi et al found that more than one-third of pediatric patients receiving treatment for newly diagnosed acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL) developed COVID-19 infection during a recent 2-year period. Study...

Lymphoma

Expert Point of View: Dipenkumar Modi, MD

The ASCO Post obtained comments on the Smart Stop study from Dipenkumar Modi, MD, a medical oncologist and hematologist at the Barbara Ann Karmanos Cancer Institute and Assistant Professor of Oncology at Wayne State University School of Medicine, Detroit. Dr. Modi applauded the investigators for...

Lymphoma

Study Finds Four-Drug Targeted Treatment Reduces Chemotherapy Requirement for Some in Large B-Cell Lymphoma

A four-drug targeted therapy regimen proved safe and effective as the first-line treatment of diffuse large B-cell lymphoma (DLBCL), achieving a 100% response rate after four cycles, researchers from The University of Texas MD Anderson Cancer Center, Houston, reported at the 2023 American Society...

Lymphoma

Expert Point of View: Carla Casulo, MD

Session co-moderator Carla Casulo, MD, offered her thoughts on the response-adapted use of ultra-low–dose radiotherapy in gastric MALT (mucosa-associated lymphoid tissue) lymphoma, as reported by the investigators from MD Anderson Cancer Center. Dr. Casulo is Associate Professor of Medicine and...

Lymphoma

‘Ultra-Low Dose’ of Radiotherapy May Be Enough in Gastric MALT Lymphoma, Study Finds

For patients with gastric MALT (mucosa-associated lymphoid tissue) lymphoma, an “ultra-low dose” of radiotherapy was as effective as the higher, standard dose in providing local control and freedom from distant relapse, researchers from The University of Texas MD Anderson Cancer Center reported at...

Lymphoma

Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?

For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...

Lymphoma

Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma

In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed activity in patients with relapsed or refractory peripheral T-cell lymphoma. Study Details In the trial, 104 patients from sites in...

Lymphoma
Hematologic Malignancies
Immunotherapy

Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy

Researchers may have uncovered a novel strategy to identify which patients may experience poorer outcomes from chimeric antigen receptor (CAR) T-cell therapy prior to treatment, according to a recent study published by Faramand et al in Blood Cancer Discovery. The findings indicate opportunities to ...

Lymphoma

Expert Point of View: Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center, New York, offered his thoughts on the combination of venetoclax and ibrutinib in the treatment of mantle cell lymphoma, as presented at the 2023 American Society of Hematology (ASH)...

Lymphoma

SYMPATICO Trial: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Relapsed Mantle Cell Lymphoma

The combination of ibrutinib and venetoclax has led to an improved progression-free survival rate in patients with relapsed or refractory mantle cell lymphoma (MCL), according to findings presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Interim analysis...

Hematologic Malignancies
Lymphoma
Leukemia

Novel CAR NK-Cell Therapy May Offer Benefit in Patients With B-Cell Malignancies

A novel chimeric antigen receptor (CAR) natural killer (NK)-cell therapy may be effective at treating patients with relapsed or refractory B-cell malignancies, according to a novel study published by Marin et al in Nature Medicine. Study Methods and Results In the new phase I/II trial, researchers...

Lymphoma

Follicular Lymphoma: Long-Term Follow-up of Rituximab Dosing Strategies Among Patients With Low Tumor Burden

As reported in the Journal of Clinical Oncology by Brad S. Kahl, MD, and colleagues, long-term follow-up of the phase III Eastern Cooperative Oncology Group RESORT study (E4402) showed that rituximab maintenance did not improve overall survival vs rituximab retreatment in rituximab induction...

Lymphoma
Issues in Oncology

Investigators Highlight Characteristics Potentially Linked to Improved CAR T-Cell Therapy Outcomes in Large B-Cell Lymphoma

Investigators have assessed whether specific tumor characteristics were associated with improved outcomes in patients with large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Locke et al in Nature Medicine. The findings may...

Lymphoma

MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma

In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...

lymphoma

Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy

Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival compared with CAR T-cell therapy, including those with early treatment failure (Abstract 781).

Lymphoma

Rituximab Maintenance in Younger Patients With Mantle Cell Lymphoma: Long-Term Follow-up

In a long-term analysis from the LYMA trial reported in the Journal of Clinical Oncology, Sarkozy et al found that rituximab maintenance following autologous stem cell transplantation (ASCT) continued to be of benefit vs observation in the first-line treatment of younger patients with mantle cell...

lymphoma

Sanjal H. Desai, MBBS, on Classical Hodgkin Lymphoma: Improving Outcomes With PD-1 Blockade

Sanjal H. Desai, MBBS, of the University of Minnesota, discusses results from a multicenter cohort, which shows that, for transplant-eligible patients with relapsed or refractory classical Hodgkin lymphoma, PD-1–based salvage therapy at any point before transplantation is associated with improved progression-free survival, compared with brentuximab vedotin or chemotherapy-based salvage regimens (Abstract 182).

leukemia
lymphoma
immunotherapy

Adam S. Kittai, MD, on Richter’s Transformation: Anti-CD19 CAR T-Cell Therapy

Adam S. Kittai, MD, of The Ohio State University, discusses his data supporting the use of CAR T-cell therapy for patients with Richter’s transformation. Given the high response rate to CD19 CAR T-cell treatment, along with early relapse in most patients, allogeneic stem cell transplantation at response should also be considered, he says (Abstract 108).

lymphoma

Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax

Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the Sympatico study, which shows the combination of ibrutinib and venetoclax improved progression-free survival vs ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma. According to Dr. Wang, these findings demonstrate a favorable benefit-risk profile for ibrutinib plus venetoclax in this patient population (Abstract LBA2).

leukemia
lymphoma

Jennifer A. Woyach, MD, on CLL/SLL: 30-Month Follow-up and Subgroup Analysis of Pirtobrutinib

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses phase I/II findings of the BRUIN study on the use of pirtobrutinib after covalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The results suggest that continuing BTK pathway inhibition following a covalent BTK inhibitor may be an important sequencing approach to consider in the treatment of CLL/SLL (Abstract 325).

lymphoma

Sarah C. Rutherford, MD, on Hodgkin Lymphoma: Nivolumab Plus AVD in Older Patients With Advanced-Stage Disease

Sarah C. Rutherford, MD, of Weill Cornell Medicine, discusses findings of the SWOG S1826 study, which showed nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free and event-free survival and seemed to be better tolerated than brentuximab vedotin plus AVD in patients aged 60 and older with advanced-stage Hodgkin lymphoma (Abstract 181).

Lymphoma
Cost of Care
Immunotherapy

Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy

The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel may be a cost-effective second-line treatment option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Choe et al in Blood Advances. Background In cases...

leukemia
lymphoma

William G. Wierda, MD, PhD, on Use of Pirtobrutinib for Richter Transformation: Updated Efficacy and Safety Results

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the phase I/II BRUIN study, which shows encouraging response and overall survival in patients with Richter transformation. Although this condition remains a challenging diagnosis, pirtobrutinib represents a potential treatment option that warrants further investigation, according to Dr. Wierda (Abstract 1737).

hematologic malignancies
leukemia
lymphoma
myelodysplastic syndromes

Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?

Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425).

Lymphoma

First-Line Treatment for Older Patients With Mantle Cell Lymphoma: Venetoclax Plus Standard Chemoimmunotherapy

The phase II PrE0405 trial met its primary endpoint, achieving a complete response rate of 85% in 33 patients with mantle cell lymphoma over age 60 who received bendamustine and rituximab, a standard chemoimmunotherapy regimen, along with venetoclax, which is investigational in this setting. The...

lymphoma

Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib

Bijal D. Shah, MD, of Moffitt Cancer Center and Research Institute, discusses a matching-adjusted indirect comparison of brexucabtagene autoleucel and pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor (Abstract 5136).

lymphoma

Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib

Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (Abstract 981).

Lymphoma

Ibrutinib/Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma

Patients with relapsed or refractory mantle cell lymphoma who received ibrutinib in combination with venetoclax experienced significantly better rates of progression-free survival compared with patients who received ibrutinib and placebo, according to findings from the international phase III...

Lymphoma
Issues in Oncology

Novel CAR T-Cell Therapy May Show Early Efficacy in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Early results from a new study have demonstrated that the novel chimeric antigen receptor (CAR) T-cell therapy AT101 resulted in favorable complete response rates at higher dose levels in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, according to new findings simultaneously...

Lymphoma
Immunotherapy

CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins

Data presented at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins (Abstract 615). While the findings do not answer the...

Lymphoma

Autologous Stem Cell Transplant vs CAR T-Cell Therapy in Patients With Relapsed LBCL in Complete Remission

For patients with large B-cell lymphoma (LBCL) who have an early relapse or whose cancer doesn’t respond to first-line treatment, randomized trials have shown that chimeric antigen receptor (CAR) T-cell therapy is superior to the historical standard of care, which included additional chemotherapy...

Lymphoma

Mantle Cell Lymphoma: Predictive Value of Measurable Residual Disease With Rituximab Maintenance

In an analysis from the European Mantle Cell Lymphoma Elderly Trial reported in the Journal of Clinical Oncology, Hoster et al found that outcomes with rituximab maintenance were better in patients aged ≥ 60 years with mantle cell lymphoma who had measurable residual disease (MRD)-negative vs...

Lymphoma
Cost of Care
Issues in Oncology

CAR T-Cell Therapy May Be Effective—but Unaffordable—as Second-Line Therapy for Patients With DLBCL

Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al in the Annals of Internal Medicine....

Lymphoma
Leukemia

FDA Grants Accelerated Approval to Pirtobrutinib for CLL/SLL

On December 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine...

Lymphoma

Effect of Bendamustine Prior to Apheresis on Outcomes in Large B-Cell Lymphoma Treated With CAR T-Cell Therapy

In a retrospective study reported in the Journal of Clinical Oncology, Iacoboni et al found that preapheresis bendamustine exposure was associated with poorer outcomes among patients with relapsed or refractory large B-cell lymphoma receiving CD19-targeted chimeric antigen receptor (CAR) T-cell...

Advertisement

Advertisement

Advertisement